Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin‐2

El-Kadi, D. A.; Wiernik, Peter H.; Tong, Teresa

doi:10.1002/ajh.21604

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicities specific to intraperitoneal immunotherapy may be anticipated based on the experience with intra-peritoneal IL-2 (30) and monoclonal antibody (31) therapy (pyrexia, abdominal pain, nausea/ vomiting). These toxicities may be cavity specific as they were far milder with intrapleural administration of the same cytokine (12,32) or antibody (14).…”

Section: Potential Drawbacks To Intra-cavitary Therapeuticsmentioning

confidence: 99%

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

et al. 2022

View full text Add to dashboard Cite

Metastasis to the pleural and peritoneal cavities is a common terminal pathway for a wide variety of cancers. This article explores how these unique environments both promote aggressive tumor behavior and suppresses anti-tumor immunity, and ways in which local delivery of protein therapeutics can leverage the contained nature of these spaces to a therapeutic advantage, achieving high intra-cavital concentrations while minimizing systemic toxicity.

show abstract

Section: Potential Drawbacks To Intra-cavitary Therapeuticsmentioning

confidence: 99%

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Other studies have also shown that intrapleural injection of IL-2 induces anti-tumour activity in patients with MPM [ 233 ]. Studies involving the intrapleural injection of IL-2 have indicated that the effusion in patients with lymphoma-related MPE has disappeared, with no effusion observed for over two years [ 234 ]. However, several clinical trials have confirmed that IL-2 has toxic effects [ 235 – 237 ].…”

Section: The Role Of Immune Microenvironment Cells In Mpe Immunotherapymentioning

confidence: 99%

Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications

Ge,

Zhao,

Liang

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor treatment. Malignant pleural effusion (MPE) is a common end-stage manifestation of lung cancer, malignant pleural mesothelioma and other thoracic malignancies, which is invasive and often accompanied by poor prognosis, affecting the quality of life of affected patients. Currently, clinical therapy for MPE is limited to pleural puncture, pleural fixation, catheter drainage, and other palliative therapies. Immunization is a new direction for rehabilitation and treatment of MPE. The effusion caused by cancer cells establishes its own immune microenvironment during its formation. Immune cells, cytokines, signal pathways of microenvironment affect the MPE progress and prognosis of patients. The interaction between them have been proved. The relevant studies were obtained through a systematic search of PubMed database according to keywords search method. Then through screening and sorting and reading full-text, 300 literatures were screened out. Exclude irrelevant and poor quality articles, 238 literatures were cited in the references. In this study, the mechanism of immune microenvironment affecting malignant pleural effusion was discussed from the perspectives of adaptive immune cells, innate immune cells, cytokines and molecular targets. Meanwhile, this study focused on the clinical value of microenvironmental components in the immunotherapy and prognosis of malignant pleural effusion.

show abstract

“…In support of this possibility, the results of a previous study showed that intrapleural IL2 administration, in a patient with PE associated with lymphoma, resulted in a long-lasting (over 2 years) absence of PE. 37 On the other hand, several clinical studies based on the systemic infusion of high doses of IL2, showed limited clinical benefits. 38,39,40 This is in part related to the fact that IL2 may not only induce proliferation and functional activation of tumor-specific effector cells, but also of regulatory T cells (Treg) leading to the impairment of the therapeutic effect.…”

Section: Introductionmentioning

confidence: 99%

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid

et al. 2017

View full text Add to dashboard Cite

Natural Killer (NK) cells are capable of recognizing and killing cancer cells and play an important role in tumor immunosurveillance. However, tumor-infiltrating NK cells are frequently impaired in their functional capability. A remarkable exception is represented by NK cells isolated from malignant pleural effusions (PE) that are not anergic and, upon IL2-induced activation, efficiently kill tumor cells. Although IL2 is used in various clinical trials, severe side effects may occur in treated patients. In this study, we investigated whether also other clinical-grade cytokines could induce strong cytotoxicity in NK cells isolated from pleural fluid of patients with primary or metastatic tumors of different origins. We show that PE-NK cells, cultured for short-time intervals with IL15, maintain the CD56 phenotype, a high expression of the main activating receptors, produce cytokines and kill tumor cells similarly to those treated with IL2. Moreover, IL15-activated PE-NK cells could greatly reduce the growth of established tumors in mice. This antitumor effect correlated with the ability of IL15-activated PE-NK cells to traffic from periphery to the tumor site. Finally, we show that IL15 can counteract the inhibitory effect of the tumor pleural microenvironment. Our study suggests that IL15-activated NK cells isolated from pleural fluid (otherwise discarded after thoracentesis) may represent a suitable source of effector cells to be used in adoptive immunotherapy of cancer.

show abstract

Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin‐2

Cited by 4 publications

References 13 publications

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid

Contact Info

Product

Resources

About